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ABSTRACT
Objective: To assess whether genetic subgroups in recent amyotrophic lateral sclerosis (ALS) tri-
als responded to treatment with lithium carbonate, but that the treatment effect was lost in a large
cohort of nonresponders.
Methods: Individual participant data were obtained from 3 randomized trials investigating the
efficacy of lithium carbonate. We matched clinical data with data regarding the UNC13A and
C9orf72 genotype. Our primary outcome was survival at 12 months. On an exploratory basis, we
assessed whether the effect of lithium depended on the genotype.
Results: Clinical data were available for 518 of the 606 participants. Overall, treatment with lith-
ium carbonate did not improve 12-month survival (hazard ratio [HR] 1.0, 95% confidence interval
[CI] 0.7–1.4; p 5 0.96). Both the UNC13A and C9orf72 genotype were independent predictors
of survival (HR 2.4, 95% CI 1.3–4.3; p 5 0.006 and HR 2.5, 95% CI 1.1–5.2; p 5 0.032,
respectively). The effect of lithium was different for UNC13A carriers (p 5 0.027), but not for
C9orf72 carriers (p5 0.22). The 12-month survival probability forUNC13A carriers treated with
lithium carbonate improved from 40.1% (95% CI 23.2–69.1) to 69.7% (95% CI 50.4–96.3).
Conclusions: This study incorporated genetic data into past ALS trials to determine treatment ef-
fects in a genetic post hoc analysis. Our results suggest that we should reorient our strategies
toward finding treatments for ALS, start focusing on genotype-targeted treatments, and stan-
dardize genotyping in order to optimize randomization and analysis for future clinical trials.
Neurology® 2017;89:1–8
GLOSSARY
ALS 5 amyotrophic lateral sclerosis; ALSFRS-R 5 Amyotrophic Lateral Sclerosis Functional Rating Scale–revised; CI 5
confidence interval; GWAS5 genome-wide association studies; HR 5 hazard ratio; IPD5 individual participant data; SNP 5
single nucleotide polymorphism.
Despite considerable efforts, riluzole is still the only drug that has been shown to increase sur-
vival in patients with amyotrophic lateral sclerosis (ALS).1 Phenotypic, genetic, and pathophys-
iologic heterogeneity form a plausible explanation for the large number of negative trials in
ALS.2 Although the mechanisms underlying ALS are not fully understood,2 it is clear that
genetic variation plays an important role in both familial and sporadic ALS.3 It is reasonable
to hypothesize that mutations in many different genes may act through several different path-
ways, but that they all cause motor neurodegeneration and manifest with an ALS phenotype. It
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may, therefore, be conceivable that different
subtypes of ALS respond differently to
disease-modifying therapies and multiple indi-
vidually tailored therapies may need to be
developed to treat the disease effectively.
Within the field of oncology, the treatment
for a specific type of malignancy often depends
on the genetic tumor characteristics. For
instance, patients with melanoma and BRAF
gene mutations have significantly improved rates
of overall and progression-free survival when
treated with a BRAF kinase inhibitor.4 It seems
that therapeutic strategies for ALS are also mov-
ing toward precision medicine and ground-
breaking targeted trials for SOD1-related ALS
have already been undertaken or are underway
with antisense oligonucleotides,5 arimoclomol
(ClinicalTrials.gov NCT00706147), and
pyrimethamine.6
In this study, we explore the possibility that
patients with genetic subgroups of ALS may
have responded to treatment in previously
conducted negative trials evaluating lithium
carbonate, but that a proportionally larger
cohort of nonresponders diluted the treatment
effect in the overall analysis.
METHODS Study design.When performing post hoc analyses
according to genotype and re-estimating treatment effects for
genetic subgroups, it is important to recognize that several problems
will arise. First, the sample size within each subgroup will decrease
dramatically and statistical power to detect treatment differences is
severely reduced. Second, obtaining DNA samples and genetic
screening is not standard practice in ALS clinical trials, thus one can
expect that genetic data will be missing. Finally, over 30 genes have
been associated with ALS. This may further reduce the statistical
power by multiple testing, but more importantly, will inflate the
false-positive risk. To overcome these issues, we performed an
individual participant data (IPD) meta-analysis of randomized
controlled trials with lithium carbonate in ALS; multiple trials with
this compound have been performed and, therefore, a large sample
size could be obtained. Moreover, an IPD meta-analysis enabled us
to reduce the false-positive risk by validating trends in independent
cohorts of patients and improve generalizability. Genetic post hoc
analyses were limited to (1) genes in which variation is relatively
common in order to ensure sufficient numbers and (2) genes
known to be modifiers of prognosis. We therefore included 2
genetic subgroups: (1) C9orf72 repeat expansion carriers and (2)
patients homozygous for the C allele of rs12608932 located in
UNC13A. Repeat expansions in C9orf72 are the most common
genetic cause of ALS and are found in approximately 5%–10% of
patients with ALS of European descent (familial and sporadic cases
combined).7,8 Genome-wide association studies (GWAS) have
repeatedly detected an association for a single nucleotide poly-
morphism (SNP: rs12608932) located in the UNC13A gene.9–11
The effect of this SNP on disease risk is modest, with an odds ratio
,1.30, but appears to convey a large effect on survival. Multiple
studies have shown that the mean survival in patients homozygous
for the C allele of rs12608932 is 6 to 12 months shorter, implying
that this SNP, or variants in linkage disequilibrium with it, is
a strong phenotypic modifier and therefore of biological rele-
vance.12–15 Approximately 16% of patients with ALS are homozy-
gous for the C allele of rs12608932.9–11
Search strategy and study selection. To identify randomized
clinical trials evaluating the efficacy of lithium carbonate in pa-
tients with ALS, we systematically searched the PubMed data-
base, Embase, Cochrane Library, Web of Science, and online
clinical trial registers (ClinicalTrials.gov, EudraCT, and IRCTN)
up to November 2016. The following search terms were used:
“amyotrophic lateral sclerosis” or “motor neuron* disease” or
“Lou Gehrig*,” and “lithium*.” Reference lists from relevant
reviews and included trials were screened in order to retrieve
additional studies. Only clinical trials published in English were
included. Each study was assessed for its methodologic quality
and risk of bias for confounding, detection, performance, attri-
tion, and reporting bias.16 We included only randomized clinical
trials with an overall low risk of bias; see table e-1 at Neurology.
org for the scoring of the included studies. We identified 4 clinical
trials that provided a minor risk of bias and subsequently con-
tacted the relevant corresponding authors for the individual
participant and genotypic data (figure e-1). Three groups (the
Netherlands, United Kingdom, and Italy) agreed to participate in
the IPD meta-analysis with genetic post hoc analyses.
Standard protocol approvals, registrations, and patient
consents. The initial trials were all conducted according to the
International Conference on Harmonisation Good Clinical Prac-
tice guidelines and with the approval of local ethical and institu-
tional review boards. All informed consents permitted the use of
IPD for future post hoc analyses, but did not specifically state
genetic post hoc analyses. We therefore obtained permission from
local ethical and institutional review boards to use existing geno-
type data from genetic studies in which trial participants were
simultaneously enrolled, or to genotype DNA samples if avail-
able. This meant that the trials and genetic studies had to be tem-
porarily deanonymized in order to match clinical data to genetic
data or DNA samples. After linking these files, the data were
reanonymized.
Genotyping of DNA samples. For all samples, C9orf72 had
either been genotyped previously or was genotyped after obtain-
ing a DNA sample using repeat-primed PCR as described pre-
viously.17 The majority (64%) of the available DNA samples from
trial participants has been included in previously conducted
GWAS using Illumina (San Diego, CA) BeadChips and provided
genotype data for rs12608932. In the remaining samples (36%),
this SNP was genotyped using Taqman (Applied Biosystems,
Foster City, CA) assays, as described previously.18
Definitions and outcome measures. Based on previous litera-
ture, patients with the UNC13A C/C genotype were classified as
UNC13A carriers in the subsequent analyses; the remaining pa-
tients with the UNC13A A/C or A/A genotype were classified as
noncarriers.14 Patients with more than 30 repeats in the C9orf72
gene were considered to be C9orf72 carriers.19 Our a priori primary
measure of treatment efficacy was death from any cause at 12
months after randomization. Due to the high adverse event and
nonadherence rate, setting the follow-up to 12 months was thought
to best capture a possible therapeutic effect and minimize the risk of
diluting the effect by the intention-to-treat principle of analysis.
Statistical analysis. All outcomes were analyzed according to
the intention-to-treat principle of analysis. We chose to analyze
the IPD from the 3 trials using a one-step meta-analytic approach.
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Previous studies have shown that a one-step meta-analytic
approach provides similar treatment effect estimates, if clustering
is appropriately accounted for, in comparison with a 2-step
approach (e.g., first summarizing the individual trial data [step
1], before pooling the effect estimates [step 2]).20 The IPD from
the 3 studies were merged together and a study indicator variable
was created. We performed a pooled analysis, while adjusting for
the clustering within studies by stratifying each analysis for the
study indicator. Missing data in covariates (1.5% of the cases had
at least one missing value) did not predict the outcome (p 5
0.50); therefore, all missing values in the covariates, except for the
genetic data, were imputed with their mean. Unlike in observa-
tional studies, mean imputation has been shown to give unbiased
estimates of the treatment effect in randomized controlled trials.21
When we analyzed genetic interactions with lithium carbonate,
we used only patients with complete genetic data, as phenotypic
variables were unable to predict the genotype accurately. We
prespecified one sensitivity analysis by estimating the treatment
effect with and without the control group of Chio et al.,22 as this
control group used a subtherapeutic dose of lithium (0.2–0.4
mEq/L instead of 0.4–0.8 mEq/L).
The time to event outcome was analyzed using Cox propor-
tional hazard models, stratified by the study indicator. Adjust-
ment for prognostic covariates substantially increases the
statistical power of Cox proportional hazard models.23 Therefore,
we selected the most important predictors by stepwise backward
selection using Akaike Information Criterion. The selected pre-
dictors were subsequently added to the model. Next, the treat-
ment indicator variable (lithium or control) was incorporated in
the model. The difference in log likelihoods between a model
with and without the treatment variable was calculated and
significance testing was done by the likelihood ratio test. Using
the same testing procedure, we evaluated whether the treatment
effect depended on the C9orf72 orUNC13A genotype by incor-
porating 2-way interaction terms. Due to the exploratory, non-
confirmatory nature of this genetic post hoc subgroup analysis,
we did not correct significance levels for multiple testing.
Results were considered significant when the 2-sided p value
was lower than 0.05.
RESULTS Data were available for 518 participants in
3 randomized clinical trials evaluating the efficacy of
lithium carbonate; study characteristics are given in
table 1. Individual data were not available from 1 of
the 4 clinical trials (study by Aggarwal et al.24), which
involved 88 participants. Baseline characteristics of
the participants included in the analysis are given in
table 2. Complete data regarding the main prognostic
confounders were available for 98.5% of the partic-
ipants (8 patients had an unknown date of onset). In
total, 261 (50.4%) patients received lithium carbon-
ate and 257 (49.6%) patients were allocated to the
control arm, in which 174 patients received placebo
(67.4%) and 83 patients a subtherapeutic dose of
lithium carbonate (32.3%). The baseline character-
istics were well-balanced between the lithium car-
bonate and control groups.
Age, Amyotrophic Lateral Sclerosis Functional
Rating Scale–revised (ALSFRS-R) slope, and vital
capacity at baseline were predictors for survival at 12
months (all p , 0.001) and were adjusted for in all
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subsequent analyses (table e-2). Overall, 75.3% (95%
confidence interval [CI] 69.9–81.2) of the patients in
the control arm and 74.7% (95% CI 69.1–80.6) in
the lithium arm were still alive at 12 months, corre-
sponding to an adjusted hazard ratio (HR) of 1.0
(95% CI 0.7–1.4; p 5 0.96; figure 1A). Excluding
the subtherapeutic control group from the analysis
did not change the treatment effect (HR 1.3, 95% CI
0.9–2.1; p 5 0.21). Next, we evaluated the pre-
specified genetic subgroup interactions in all patients
with genetic data (n 5 269); the baseline character-
istics are given in tables 3 and e-3. Both the UNC13A
and C9orf72 genotype were independent predictors
for 12-month survival, with an adjusted HR of 2.4
(95% CI 1.3–4.3; p 5 0.006) and HR 2.5 (95% CI
1.1–5.2; p 5 0.032), respectively (figure 1B). The
overall effect of lithium carbonate in the patients with
genetic data remained futile (HR 0.8, 95% CI 0.4–
1.4; p 5 0.39).
The treatment effect was different for the
UNC13A carriers (n 5 46; p 5 0.027) but not for
the C9orf72 carriers (n 5 25; p 5 0.22). Lithium
carbonate in UNC13A carriers resulted in a 70%
reduction in the number who died during the 12-
month follow-up period as compared to the placebo
group (HR 0.3, 95% CI 0.1–0.9), whereas the non-
carriers did not benefit from lithium carbonate (HR
1.2, 95% CI 0.6–2.3; figure 2). The significant treat-
ment interaction with UNC13A genotype remained
after correcting for the interaction between the
C9orf72 genotype and lithium (p5 0.020) or exclud-
ing the control group from the LITALS study (p 5
0.047). The interaction between lithium treatment
and UNC13A was homogenous across the 3 different
studies (3-way interaction Cox model; p 5 0.99;
figure e-2). Baseline characteristics of the UNC13A
carriers are given in table e-3 (n 5 46). The crude
Kaplan-Meier estimate of 12-month survival proba-
bility for UNC13A carriers improved from 40.1%
(95% CI 23.2–69.1) in the control group (n 5 26)
to 69.7% (95% CI 50.4–96.3) in the lithium group
(n5 20) (p5 0.056). When we adjusted for baseline
inequalities (vital capacity and sex), lithium treatment
was effective (p 5 0.039), and remained so when we
additionally corrected for age and ALSFRS-R slope
(p 5 0.040).
DISCUSSION In this study, we have shown the
importance of including genetic information in clin-
ical trials for ALS. Our results reveal that even within
a well-defined and selected trial population, consid-
erable differences in the primary outcome can be
expected for patients with either the UNC13A C/C
genotype or C9orf72 repeat expansion. Interestingly,
we showed that the overall meta-analysis of trials with
lithium carbonate in ALS is futile, but that a genetic
subgroup of patients (UNC13A C/C genotype) may
benefit from this treatment. Due to the small sample
size of this genetic subgroup (fewer than 20% of the
cases), the signal indicating response may have been
lost within the large group of nonresponders.
Although our genetic knowledge about causative
and disease-modifying genes in ALS is growing expo-
nentially,3 we have not yet managed to translate these
novel findings into effective therapeutic strategies. To
date, only 2 targeted (phase I) genetic trials have been
completed and a number of targeted trials are cur-
rently underway.5,6 By showing that genetic variation
in ALS genes significantly influences the primary out-
come measure of a clinical trial and may alter treat-
ment response, we have demonstrated the importance
of incorporating genetic data in the analysis of ALS
trials. Unequally balanced genotypes across treatment
and control groups, especially in smaller studies, may
greatly influence the false-positive and false-negative
rates and the validity of clinical trials in ALS as
a whole. For instance, the probability of an imbalance
larger than 10% between treatment arms, if the prog-
nostic factor is present in 15% of the cases (like UN-
C13A C/C genotype), is 0.24 and 0.10 for trial sizes
of n 5 50 and n 5 100, respectively.25 It might
therefore even be conceivable that the high false-
positive rate of the phase II trial in ALS2 is partially
caused by an imbalance of disease-modifying genetic
Table 2 Clinical characteristics of patients included in pooled analysis
LITALS (n 5 171) LiCALS (n 5 214) LITRA (n 5 133) Total (n 5 518) Lithium (n 5 261) Control (n 5 257)
Age at randomization, y 58 (11) 60 (11) 58 (12) 59 (11) 58 (12) 59 (11)
Female 71 (42) 66 (31) 53 (40) 190 (37) 96 (37) 94 (37)
Disease duration at randomization, mo 19 (10) 19 (8) 15 (8) 18 (9) 18 (9) 18 (9)
Bulbar site of onset 41 (24) 47 (22) 38 (29) 126 (24) 62 (24) 64 (25)
Predicted upright vital capacity 85 (21) 91 (18) 95 (17) 90 (19) 90 (19) 90 (19)
ALSFRS-R 37 (6) 38 (6) 40 (5) 38 (6) 39 (6) 38 (6)
Abbreviations: ALSFRS-R 5 Amyotrophic Lateral Sclerosis Functional Rating Scale–revised.
Data are mean (SD) or n (%).
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variants between treatment arms in these studies. The
false-positive risk may be further inflated by the lim-
ited sample size often used for phase II ALS trials.
Lithium for ALS first came into the spotlight after
an initial report that suggested an important improve-
ment of survival following lithium treatment.26 Our
study, combining the results of 3 randomized
placebo-controlled trials, excludes an overall treat-
ment effect similar to riluzole. We had 89% power
to detect a 10% absolute increase in survival.27 We
found, however, that the treatment effect of lithium
carbonate was not homogenous across patients. The
Figure 1 Pooled analysis of treatment effect for lithium carbonate and 12-month survival for each genetic
subgroup
Pooled 12-month survival in 3 clinical trials evaluating the efficacy of lithium carbonate. (A) Overall treatment effect of lith-
ium carbonate was nonsignificant (hazard ratio [HR] 1.0, 95% confidence interval [CI] 0.7–1.4). (B) There was a significant
effect of genetic subgroups on 12-month survival, irrespective of treatment arm, within the clinical trials (UNC13A HR 2.4,
95% CI 1.3–4.3; p 5 0.006; and C9orf72 HR 2.5, 95% CI 1.1–5.2; p 5 0.032). Three patients had both risk variants of
UNC13A and C9orf72; the number at risk of these patients is merged with the UNC13A carriers.
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observation that patients with ALS homozygous for
the C allele of rs12608932 in UNC13A may benefit
from lithium may warrant further research. The
UNC13A protein is involved in synaptic vesicle mat-
uration and neuronal outgrowth.28 Lithium has been
shown to influence many pathways, including the
Table 3 Comparison of the baseline characteristics between patients with and without genetic data
Patients without genetic
data (n 5 249)
Patients with genetic data
Total (n 5 269) Lithium (n 5 129) Control (n 5 140)
Age at randomization, y 60 (11) 58 (11) 57 (11) 59 (11)
Women 83 (33) 107 (40) 54 (42) 53 (38)
Disease duration at randomization, mo 17 (8) 18 (9) 18 (9) 19 (9)
Bulbar site of onset 66 (27) 60 (22) 27 (21) 33 (24)
Predicted upright vital capacity 88 (19) 92 (19) 92 (19) 91 (19)
ALSFRS-R 38 (6) 39 (6) 39 (6) 39 (6)
C9orf72 expansion carriers 249 (48)a 25 (9) 14 (11) 11 (8)
LiCALS 157 (73)a 6 (11) 2 (7) 4 (13)
LITALS 73 (57)a 8 (8) 5 (10) 3 (6)
LITRA 19 (14)a 11 (10) 7 (13) 4 (7)
UNC13A C/C genotype carriers 249 (48)a 46 (17) 20 (16) 26 (19)
LiCALS 157 (73)a 11 (19) 6 (22) 5 (17)
LITALS 73 (57)a 18 (18) 9 (19) 9 (18)
LITRA 19 (14)a 17 (15) 5 (9) 12 (20)
Abbreviations: ALSFRS-R 5 Amyotrophic Lateral Sclerosis Functional Rating Scale–revised.
Data are mean (SD) or n (%). Three patients had both risk variants of UNC13A and C9orf72.
a Number (%) missing.
Figure 2 Cox proportional hazards model of 12-month survival and the interaction of lithium carbonate with
UNC13A genotype
Incorporating interaction terms between treatment arm (control or active) and UNC13A carrier status revealed that the
effect of lithium carbonate significantly depended on the UNC13A carrier status (p 5 0.027). Lithium carbonate improved
the 12-month survival in individuals with the UNC13A C/C genotype, but had no effect in noncarriers.
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induction of sprouting of pyramidal neurons in the
corticospinal tract and the promotion of synaptogen-
esis, and plays a role in autophagy.29 All these mech-
anisms are potentially relevant to ALS. However, it
has also been shown that rs12608932 influences the
expression of the nearby KCNN1 gene,30,31 which
encodes a potassium calcium-activated channel. It is
therefore also possible that lithium influences
KCCN1 or acts through other pathways.
Without a solid understanding of the biological
interaction between the treatment and pathophysio-
logic pathway, it is challenging to robustly identify
the responder group, without increasing the risk of
drawing false-positive or false-negative conclusions.32
We reduced this likelihood by only testing 2 prespe-
cified pharmacogenetic interactions and selecting
genotypes that are relatively commonly occurring in
the general ALS population. Moreover, by using data
from 3 independent cohorts, we could assess whether
the signal is consistent across studies. Nevertheless,
the evidence we provide regarding the interaction
between UNC13A and lithium carbonate is still
exploratory and hypothesis-generating. This finding
does, however, warrant further exploration of lithium
carbonate in a well-balanced, blinded, randomized
clinical trial specifically targeted at patients with
ALS and the UNC13A C/C genotype. Such a trial,
and future genetic trials for ALS in general, will
require intensive international cooperation to obtain
large sample sizes of patients with ALS with a specific
genotype. For instance, the prevalence of the
UNC13A C/C genotype is 12.2%–19.5%9,12,15
among patients with ALS. This would result in
a screening failure rate of 80.5%–87.8% on genotype
alone. Large numbers of patients will need to be ap-
proached to ensure an acceptable phase III clinical
trial sample size. For instance, 140 UNC13A carriers
would be required to detect a HR of 0.62 by a 2-sided
log-rank test with 90% power, assuming a 1-year
survival of 50% in the placebo group, indicating that
in the worst case (UNC13A prevalence of 12.2%),
approximately 1,100 patients need to be genotyped.
ALS is both clinically and genetically a highly het-
erogeneous disease and it is this complexity that seems
to complicate the development of effective treatment
for our patients. Even in carefully selected trial popu-
lations, the genotype significantly affected the pri-
mary outcome measure—survival—in ALS trials.
The assumption of a homogenous treatment effect
across patients with ALS, for lithium specifically
and ALS trials in general, seems no longer tenable
and genetic subgroups of patients may modify the
treatment effect. The results from this study suggest
that we should reorient our strategies toward finding
treatments for ALS and start focusing on genotype-
targeted treatments and standardize genotyping in
order to optimize randomization and analysis in
ALS clinical trials.
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